ASCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order of components, figure ...

Anti–vascular endothelial growth factor therapy enhances PD-1 inhibitor activity in preclinical models and has been used to treat perilesional cerebral edema and radiation necrosis. Thirty-seven ...

Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01) The management of renal cell carcinoma (RCC) has seen significant ...

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group Treatment stratification in ALL ...

Improving prostate cancer risk stratification using spatial single-cell tumor profiling. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...

Development of an ex-vivo platform to model immunotherapy in kidney cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full ...

Complications after transurethral resection of bladder tumor: Findings from the 2022 ACS NSQIP database. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Serum biomarkers in metastatic castration-resistant prostate cancer (mCRPC) patients receiving [177Lu]Lu-PSMA-617 therapy: Post hoc analysis of a phase II clinical trial. Individual patient data (IPD) ...

Clinical protocols to monitor efficacy of [177Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...

This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text component.